Association between response to triptans and response to erenumab: real-life data

Background: Triptans and erenumab are both migraine-specific agents acting on the calcitonin gene-related peptide pathway. Therefore, response to triptans might be associated with response to erenumab. Main body: In our study, consecutive patients referring to the Headache Centers of the Abruzzo region from January 2019 to March 2020 and treated with erenumab were interviewed about past use and efficacy of triptans. Triptan users were classified as 'triptan responders' if they were headache-free 2 h after treating >= 3 migraine attacks with >= 1 triptan. We considered patients as 'erenumab responders', if they had a >= 50% mean reduction in monthly migraine days between the 4th and the 6th month from treatment start compared with baseline. Of 91 triptan users, 73 (80.2%) were triptan responders and 58 (63.7%) were erenumab responders. The odds ratio of being erenumab responder was 3.64 (95% CI, 1.25-10.64) for triptan users as compared to non-users. (P = 0.014). Besides, starting erenumab improved triptan response in both erenumab responders and non-responders. Conclusions: Our data of an association between response to triptans and response to erenumab can be useful for patient advice and to improve the understanding of migraine pathophysiology and treatment.

Automated summary

The study found that 80.2% of triptan users were triptan responders, while 63.7% were erenumab responders. The response to triptans was associated with the response to erenumab in the study, with a significant odds ratio for erenumab response in triptan users compared to non-users. Starting erenumab also improved triptan response in both erenumab responders and non-responders, suggesting potential benefits for migraine treatment.